Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Implications for IV posaconazole dosing in the era of obesity.

Wasmann RE, Smit C, van Donselaar MH, van Dongen EPA, Wiezer RMJ, Verweij PE, Burger DM, Knibbe CAJ, Brüggemann RJM.

J Antimicrob Chemother. 2020 Apr 1;75(4):1006-1013. doi: 10.1093/jac/dkz546.

2.

Correction to: Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Nonobese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Pharm Res. 2020 Jan 9;37(2):32. doi: 10.1007/s11095-020-2756-7.

3.

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals.

Smit C, Wasmann RE, Goulooze SC, Wiezer MJ, van Dongen EPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Br J Clin Pharmacol. 2020 Feb;86(2):303-317. doi: 10.1111/bcp.14144. Epub 2020 Jan 7.

4.

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.

Wasmann RE, Smit C, van Dongen EPH, Wiezer RMJ, Adler-Moore J, de Beer YM, Burger DM, Knibbe CAJ, Brüggemann RJM.

Clin Infect Dis. 2019 Sep 7. pii: ciz885. doi: 10.1093/cid/ciz885. [Epub ahead of print]

PMID:
31588493
5.

Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Pharm Res. 2019 May 30;36(8):112. doi: 10.1007/s11095-019-2651-2. Erratum in: Pharm Res. 2020 Jan 9;37(2):32.

6.

A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients.

Smit C, Wasmann RE, Goulooze SC, Hazebroek EJ, Van Dongen EPA, Burgers DMT, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Clin Pharmacokinet. 2019 Oct;58(10):1333-1343. doi: 10.1007/s40262-019-00762-4.

7.

Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults.

Wasmann RE, Smit C, Ter Heine R, Koele SE, van Dongen EPH, Wiezer RMJ, Burger DM, Knibbe CAJ, Brüggemann RJM.

J Antimicrob Chemother. 2019 Apr 1;74(4):978-985. doi: 10.1093/jac/dky554.

PMID:
30649375
8.

Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults.

Wasmann RE, Ter Heine R, van Dongen EP, Burger DM, Lempers VJ, Knibbe CA, Brüggemann RJ.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00063-18. doi: 10.1128/AAC.00063-18. Print 2018 Jul.

9.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):263. doi: 10.1093/jac/dkx425. No abstract available.

PMID:
29112717
10.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):134-142. doi: 10.1093/jac/dkx354. Erratum in: J Antimicrob Chemother. 2018 Jan 1;73(1):263.

PMID:
29048485
11.

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.

Wasmann RE, Muilwijk EW, Burger DM, Verweij PE, Knibbe CA, Brüggemann RJ.

Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5. Review.

Supplemental Content

Loading ...
Support Center